Cargando…

Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction

Leucine Rich Repeat Kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson’s disease (PD)(1) and is also linked to its idiopathic form(2). LRRK2 is proposed to function in membrane trafficking(3) and co-localizes with microtubules(4). Despite LRRK2’s fundamental importance for unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Deniston, CK, Salogiannis, J, Mathea, S, Snead, DM, Lahiri, I, Matyszewski, M, Donosa, O, Watanabe, R, Böhning, J, Shiau, AK, Knapp, S, Villa, E, Reck-Peterson, SL, Leschziner, AE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726071/
https://www.ncbi.nlm.nih.gov/pubmed/32814344
http://dx.doi.org/10.1038/s41586-020-2673-2
Descripción
Sumario:Leucine Rich Repeat Kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson’s disease (PD)(1) and is also linked to its idiopathic form(2). LRRK2 is proposed to function in membrane trafficking(3) and co-localizes with microtubules(4). Despite LRRK2’s fundamental importance for understanding and treating PD, there is limited structural information on it. Here we report the 3.5Å structure of the catalytic half of LRRK2, and an atomic model of microtubule-associated LRRK2 built using a reported 14Å cryo-electron tomography in situ structure(5). We propose that the conformation of LRRK2’s kinase domain regulates its microtubule interaction, with a closed conformation favoring oligomerization on microtubules. We show that the catalytic half of LRRK2 is sufficient for filament formation and blocks the motility of the microtubule-based motors kinesin-1 and cytoplasmic dynein-1 in vitro. Kinase inhibitors that stabilize an open conformation relieve this interference and reduce LRRK2 filament formation in cells, while those that stabilize a closed conformation do not. Our findings suggest that LRRK2 can act as a roadblock for microtubule-based motors and have implications for the design of therapeutic LRRK2 kinase inhibitors.